Log In
Print this Print this

Xadago, safinamide (formerly PNU-151774E)

  Manage Alerts
Collapse Summary General Information
Company Newron Pharmaceuticals S.p.A.
DescriptionAlpha-aminoamide derivative that acts as a reversible monoamine oxidase B (MAO-B) and dopamine reuptake inhibitor while reducing glutamatergic activity
Molecular Target Monoamine oxidase B (MAO-B)
Mechanism of ActionMonoamine oxidase B (MAO-B) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentApproved
Standard IndicationParkinson's disease (PD)
Indication DetailsTreat early Parkinson's disease (PD); Treat mid- to late-stage Parkinson's disease (PD); Treat Parkinson's disease (PD)
Regulatory Designation

EU - Standard Review (Treat Parkinson's disease (PD));
Switzerland - Standard Review (Treat Parkinson's disease (PD))


Meiji Seika Pharma Co. Ltd.; Zambon Co. S.p.A.

 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today